Antipsychotic Medication Extended Dosing Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00431574 |
Recruitment Status
:
Completed
First Posted
: February 6, 2007
Last Update Posted
: February 26, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia | Procedure: dosing | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Antipsychotic Medication Extended Dosing Study |
Study Start Date : | August 2002 |
Actual Primary Completion Date : | June 2007 |
Actual Study Completion Date : | October 2007 |

- Clinical Global Impression every 2 weeks
- Simpson and Angus Rating Scale for Extrapyramidal Effects every 2 weeks
- Barnes Rating Scale for Drug-Induced Akathisia every 2 weeks
- Abnormal Involuntary Movement Scale every 2 weeks
- Drug Attitude Inventory every 2 weeks
- Calgary Depression Scale for Schizophrenia every 2 weeks
- Brief Psychiatric Rating Scale every 2 weeks

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- DSM-IV diagnosis of schizophrenia or schizo-affective disorder
- Capacity to provide written, informed consent
- Stabilized* on a single oral antipsychotic for at least three months (excluding CLOZAPINE or QUETIAPINE)
- Evidence of compliance with previous antipsychotic treatment, i.e. greater than 90% * defined as 2 consecutively identical CGI evaluations (screening and baseline, at least one week apart)
Exclusion Criteria:
- exposure to depot antipsychotic during 12 months prior to enrollment
- substance-related disorders according to DSM-IV

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00431574
Canada, Ontario | |
Centre for Addiction and Mental Health | |
Toronto, Ontario, Canada, M5T 1R8 |
Principal Investigator: | Gary J Remington, MD, PhD | Centre for Addiction and Mental Health |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Dr. Gary Remington, Centre for Addiction and Mental Health |
ClinicalTrials.gov Identifier: | NCT00431574 History of Changes |
Other Study ID Numbers: |
234/2003 |
First Posted: | February 6, 2007 Key Record Dates |
Last Update Posted: | February 26, 2008 |
Last Verified: | February 2008 |
Keywords provided by Centre for Addiction and Mental Health:
schizophrenia schizoaffective antipsychotic randomized control trial |
Additional relevant MeSH terms:
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Antipsychotic Agents |
Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Psychotropic Drugs |